GlassScriptPhysician profile
Jason M Jacobs
NPI 1750379954
$2,603.16
in general payments reported to CMS, 2019-2025
25 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $77.17 · 2021: $332 · 2022: $261 · 2023: $204 · 2024: $383 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $821.32 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Bausch & Lomb Americas INC. | $311.64 | 2024-2025 | Xiidra, Miebo |
| Abbvie INC. | $297.00 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $129.56 | 2019-2024 | Tecnis Simplicity |
| Novartis Pharmaceuticals Corporation | $114.95 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $113.80 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $104.58 | 2019-2024 | Cequa |
| Optos, INC. | $92.08 | 2019 | |
| New World Medical,INC. | $69.64 | 2022-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Akorn, INC. | $63.11 | 2019-2020 | |
| Allergan, INC. | $59.25 | 2019-2022 | |
| Horizon Therapeutics Plc | $54.47 | 2019-2023 | Tepezza |
| Akorn Operating Company LLC | $51.90 | 2021 | |
| Apellis Pharmaceuticals, INC. | $51.77 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $43.62 | 2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $43.53 | 2021 | |
| Alexion Pharmaceuticals, INC. | $27.23 | 2023 | Soliris |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.28 | 2019-2021 | |
| Shire North American Group INC | $24.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $22.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.26 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.75 | 2025 | Vevye |
| Thea Pharma INC. | $13.76 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.